Maurice Perol, MD, Léon Bérard Cancer Center

home / authors / maurice-perol-md-l-on-b-rard-cancer-center

Articles

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center

October 20th 2020

Practical Implications of ADAURA in NSCLC

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center

October 20th 2020

Unprecedented Results from ADAURA

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center

October 20th 2020

Adjuvant Approaches in EGFR+ NSCLC

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center

October 20th 2020

Standard of Care for EGFR+ ES-NSCLC

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center

October 20th 2020

Testing for EGFR in NSCLC Worldwide

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center

October 20th 2020

Molecular Testing in Early-Stage NSCLC

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center

October 20th 2020

Determining Resectability in ES-NSCLC

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center

October 20th 2020

Clinical Evaluation of ES-NSCLC in Japan

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center

October 20th 2020

Dr Ramalingam on Osimertinib Post-Chemoradiotherapy in Unresectable, Stage III, EGFR-Mutated NSCLC

First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC

Addition of Atezolizumab to Chemotherapy and Bevacizumab Does Not Yield Benefit in Ovarian Cancer

Liver Transplantation Plus Chemotherapy Improves 5-Year OS Rate in Patients With CRC Liver Metastases

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512